Skip to content

Investigating the Effect of Zini Xiaopi Formula on Spleen Qi Deficiency Syndrome Gastric Cancer-Related Fatigue Through Oral Microbiota Modulation

Investigating the Effect of Zini Xiaopi Formula on Spleen Qi Deficiency Syndrome Gastric Cancer-Related Fatigue Through Oral Microbiota Modulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001675
Enrollment
Unknown
Registered
2025-09-04
Start date
2025-09-20
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer-Related Fatigue

Interventions

Control group:Routine treatment
Experimental group:Routine treatment+Orally administered Zini Xiaopi Formula

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Met diagnostic criteria for gastric cancer AND received platinum-based (e.g. oxaliplatin) or fluoropyrimidine-based (e.g. capecitabine) standardized chemotherapy regimens; 2. Diagnosed with spleen qi deficiency syndrome per TCM diagnostic criteria; 3. Met Cancer-Related Fatigue (CRF) diagnostic criteria AND exhibited fatigue symptoms on validated scales; 4. Aged 18-75 years; 5. Expected life expectancy =6 months; 6. Hemoglobin level =90 g/L; 7. Karnofsky Performance Status (KPS) score =60; 8. Demonstrated good compliance and willingness to cooperate with treatment protocols; 9. Voluntarily enrolled and provided signed informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of allergy to Chinese herbal medicine or inability to tolerate herbal therapy; 2. Concurrent users of hormones or psychostimulants; 3. Pregnant/lactating women or patients with psychiatric disorders; 4. Individuals unable to receive oral administration; 5. Patients with severe acute/chronic diseases of cardiac pulmonary hepatic renal immune or hematopoietic systems or showing significant organ dysfunction: - Serum creatinine >1.5×ULN (upper limit of normal) - ALT or AST =5×ULN - Total bilirubin >1.5×ULN 6. Oral/abdominal discomfort within 4 weeks prior to saliva collection with concomitant antibiotic/probiotic use.1

Design outcomes

Primary

MeasureTime frame
Brief Fatigue Inventory;TCM syndrome score scale;Piper Fatigue Revised Scale;

Secondary

MeasureTime frame
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) Version 3.0;Karnofsky Performance Status scales;Pittsburgh sleep quality index;

Countries

China

Contacts

Public ContactDehou Deng

Zhejiang Cancer Hospital

ddh80114@163.com+86 135 8878 9868

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026